49 results about "Chronic viral hepatitis B" patented technology

The invention provides detoxification strengthening powder for treating chronic viral hepatitis B, which comprises the following components in parts by weight: 15-25 parts of vinegar radix bupleuri, 15-25 parts of honey-fried licorice root, 60-75 parts of poria cocos, 60-75 parts of rhizoma atractylodis macrocephalae, 60-75 parts of radix paeoniae alba, 30-50 parts of angelica sinensis, 85-100 parts of honeysuckle flower, 80-100 parts of sculellaria barbata, 60-75 parts of raw astragalus membranaceus, 90-100 parts of the root of red-rooted salvia, 80-100 parts of raw barley, 30-45 parts of schisandra chinensis, 35-50 parts of the root bark of the peony tree, 35-50 parts of medlar and 30-50 parts of glossy privet fruit. By adopting multi-directional, multi-target and multi-link comprehensive treatment according to multiple complex mechanisms of diseases, the composition provided by the invention has the functions of balancing yin and yang and regulating the qi and blood of the chronic hepatitis B patients, so that the chronic hepatitis B patients have full healthy atmosphere, and the pathogenic factors can be removed. Each single medicine is not powerful; the components have different effects, for example, the honeysuckle flower can clear away heat and toxic materials but cannot replace angelica sinensis to nourish and regulate blood, and even more, the honeysuckle flower does not have the effect of medlar for nourishing liver and kidney. Each medicine should be reasonably combined with other medicines, so that both symptoms and root causes can be resolved, and a more remarkable clinical treatment effect can be obtained.

The invention relates to a medicinal composition for treating chronic hepatitis B, liver cirrhosis and liver fibrosis, which is mainly prepared from Chinese medicaments such as raidx astragali, pseudo-ginseng, fried turtle shell and fiveleaf gynostemma herb, can be prepared into conventional medicinal preparation, and is used for treating the chronic hepatitis B, the liver fibrosis, the liver cirrhosis and chemical liver injury.

The invention discloses a liver treating drink for treating acute and chronic viral hepatitis B, which is prepared from the following Chinese herbal medicines: kummerowia striata, red sage root, oldenlandia diffusa, phyllanthus urinaria, fried bighead atractylodes rhizome, stringy stonecrop, cogongrass rhizome, gizzard pepsin, self-heal, boneset and oriental wormwood. The invention also relates to a preparation method of the drink and an application of the drink for treating viral hepatitis B. The clinical test shows that the drink has the functions of eliminating hepatitis B virus, regulating immunity, protecting the liver, reducing enzyme and the like, and has obvious effects on treating acute icteric hepatitis, anicteric hepatitis and chronic viral hepatitis B.

A Chinese medicine in the form of particles for treating chronic hepatitis B is prepared from 12 Chinese-medicinal materials including pseudostellaria root, wolfberry fruit, red peony root, liquorice root, etc through proportionally pretreating, concentrating, drying, pulverizing and granulating. Its advantage is high curative effect (93.66%).

The invention provides a traditional Chinese medicine composition for treating chronic hepatitis B and hepatitis B related decompensated hepatic cirrhosis. The traditional Chinese medicine compositionat least comprises the following medicinal raw materials: astragalus membranaceus, oriental wormwood, scutellaria baicalensis, coptis chinensis, golden cypress, curcuma zedoary, processed turtle shell, scorched hawthorn fruit, radix paeoniae alba, campsis grandiflora, bran-fried atractylodes macrocephala koidz, poria cocos, radix bupleuri and oldenlandia diffusa. The traditional Chinese medicinecomposition has the advantages as follows: on the basis of realizing the treatment of chronic hepatitis B and liver cirrhosis, the development evolution of chronic hepatitis B-liver cirrhosis-liver cancer is cut off, the vacancy that chronic viral hepatitis B and hepatic cirrhosis cannot be simultaneously treated at present is made up, the occurrence of hepatic cirrhosis and liver cancer is reduced, the annual incidence rate of hepatic cirrhosis of a chronic hepatitis B patient is reduced to 1% from 2-10%, and the annual incidence rate of primary liver cancer of a hepatitis B related decompensated hepatic cirrhosis patient is reduced to 1% from 3%-6%, so that the lifetime of the patient is prolonged, the burden of the patient is reduced, and medical expenditure is saved for the country. Inaddition, the invention also provides other nine traditional Chinese medicine compositions obtained by the basic formula.

The invention belongs to the technical field of biomedicine, relates to a hepatitis B virus (HBV) vaccine and a preparation method thereof and further relates to application of the vaccine in prevention of hepatitis B virus infection and treatment of chronic hepatitis B (CHB) infection and application of the vaccine in cooperation with an HBsAg vaccine in treatment of CHB. The vaccine comprises a hepatitis B virus envelope protein preS1 region, can effectively prevent HBV from infecting a host, has a treatment effect on chronic hepatitis virus infection, and achieves a more remarkable effect than that of a traditional HBV vaccine in the prior art.

The invention discloses a longevity plasma cell capable of secreting a PD-1 antibody as well as a preparation method and application of the longevity plasma cell. The method specifically comprises thefollowing steps: integrating a PD-1 antibody gene into a B cell at a fixed point to obtain a genetically engineered B cell; and inducing the genetically engineered B cell into a longevity plasma cellsecreting a PD-1 antibody. The prepared longevity plasma cell capable of secreting the PD-1 antibody has typical phenotype and transcription characteristics of the longevity plasma cell; in addition,a large number of PD-1 antibodies can be continuously secreted, PD-1 antibody drug-mediated tumor immunotherapy is expected to be replaced, Meanwhile, a new thought is provided for tumor adoptive cellular immunotherapy. Moreover, the antibody gene is introduced into B cells to be induced into long-life plasma cells capable of continuously secreting a large number of antibodies; the new thought therapy for treating the long-life plasma cell transfused patient not only can be used for treating various tumors, but also has a wide application prospect in various infectious diseases such as AIDS (acquired immune deficiency syndrome) and chronic viral hepatitis B, and protein-deficient diseases such as hemophilia.

The invention is a compound recipe Liuyueqing capsule (LYQC) composed of 15g of plug malan, 15g of oldenlandia diffusa, 15g of cape jasmine root, 15g of herba scutellariae barbatae, 15g of lawn pennywort herb and 15g of stringy stonecrop, which aims to provide a new effective Chinese herbal medicine composition for treating hepatitis B and solve the problem of bad hepatitis B therapeutic effect. Long term and plentiful investigations find that the LYQC can effectively protect the acute liver injuries in mice induced by carbon tetrachloride, Acetaminophen and D-Galactosamine; and can obviously restrict HBsAg and HBeAg in serum in vitro and HBV in vivo and in vitro with rather low toxicity. The investigations show that the invention can provide new medicament with good curative effect for acute viral hepatitis B and CVH chronic viral hepatitis B, hepatic fibrosis and hepatitis B virus carriers.

The invention relates to a Chinese medicinal formula for treating chronic virus B hepatitis, which is a worldwide disease caused by hepatitis B virus. According to statistics, the number of asymptomatic HBV (hepatitis B virus) carrier exceeds 280 million all over the world, and China accounts for 45%. Most of the patients are asymptomatic, and 1/3 of the patients show liver damage clinically. Currently, the number of hepatitis B patients in China totals 30 million. Hepatitis B is characterized by slow onset, and common subclinical and chronic types. And patients with persistent positive non-icteric HBsAg (hepatitis B surface antigen) are likely to become chronic. The disease of chronic virus B hepatitis is mainly transmitted by means of blood, mother-baby, and sexual contact. Virus B hepatitis vaccines in the traditional sense can prevent and treat a lot of hepatitis viruses effectively, but due to individual differences, many patients still show maladjustment.

The invention discloses radix bupleuri and baical skullcap root detoxification granules which are compounded by radix bupleuri, baical skullcap root, white paeony root, herba lycopi, Chinese angelica, salvia miltiorrhiza, Indian buead, bighead atractylodes rhizome, turtle shell, tortoise plastron, oldenlandia diffusa, sculellaria barbata, rhizoma cyperi, Jiaozha, malt, medicated leaven, honey-fried licorice root and Chinese date. The materials are crushed into granules by employing a bluestone tool and are allowed to pass through a 6# (150mu m+/-6.6mu m) nylon sieve with the particle size of 100 meshes, and the prepared granules are filled in an aluminum foil bag for later use. The radix bupleuri and baical skullcap root detoxification granules have the beneficial effects that the granules have the good effects of resisting hepatitis B virus, improving the symptoms, improving the liver function, regulating the immunologic function and preventing hepatic fibrosis and cirrhosis in the treatment of chronic viral hepatitis B, and the total effective rate is 93.3 percent.

The invention discloses a humanized single chain antibody of anti-hepatitis B virus surface antigen a determinant, the amino acid sequence thereof is SEQ ID NO: 1. The VH amino acid sequence of the antibody is SEQ ID NO: 2, and the VL amino acid sequence of the antibody is SEQ ID NO: 3. The humanized single chain antibody of the anti-hepatitis B virus surface antigen a determinant is used for preparing preventive passive immunity drug or preparing medicines for treating chronic viral hepatitis B.

The invention aims to solve the problem that a non-invasive diagnosis method is hardly available for confirming the hepatic pathological state of people with alanine transaminase (ALT) being less than two times of an upper normal limit in the prior art, and provides a system for predicting a liver inflammatory degree of a chronic viral hepatitis B patient with alanine transaminase being less than two times of the upper normal limit. The system comprises a detection module, an Inf-index1 calculation module and a liver inflammatory degree prediction module, wherein the detection module is used for detecting hepatitis B core antibody content, glutamic oxalacetic transaminase content and albumin content in serum of the chronic viral hepatitis B patient with alanine transaminase being less than two times of the upper normal limit; the Inf-index1 calculation module is used for calculating Inf-index1 according to the hepatitis B core antibody content, the glutamic oxalacetic transaminase content and the albumin content; the liver inflammatory degree prediction module is used for predicting the liver inflammatory degree of the chronic viral hepatitis B patient with alanine transaminase being less than two times of the upper normal limit. As proved by clinical test, the system has high prediction accuracy on the inflammatory degree of the chronic viral hepatitis B patient with alanine transaminase being less than the double upper normal limit, and a novel method is provided for clinical diagnosis.

The invention discloses a traditional Chinese medicine composition for treating chronic virus b hepatitis through immunity regulation and control, which is prepared from the following raw medicinal materials in parts by weight: 20-10 parts of glossy privet fruit, 20-10 parts of herba epimedii, 20-10 parts of ternate buttercup root, 20-10 parts of root-bark of tree peony, 10-5 parts of picrorhiza rhizome and 10-5 parts of green tangerine orange peel. Shown by clinical practice, the traditional Chinese medicine composition of the invention has immunoregulation effect similar to that of interferon, and has a certain correction effect on the immunity tolerance induced by hepatitis b virus infection.